Management of Essential Thrombocythemia

Risk-Based Treatment Algorithm

The American Society of Clinical Oncology recommends hydroxyurea plus low-dose aspirin for high-risk essential thrombocythemia patients, as this combination has been proven superior to anagrelide plus aspirin in reducing thrombotic complications, major bleeding, and progression to myelofibrosis 1
For high-risk patients, the National Comprehensive Cancer Network recommends initiating combination therapy with hydroxyurea as first-line cytoreductive agent at 15-20 mg/kg/day, titrating to achieve platelet count <400 × 10⁹/L, and low-dose aspirin 81-100 mg daily for thrombosis prevention 1, 3

The National Comprehensive Cancer Network recommends aspirin alone for low-risk and intermediate-risk patients age 40-59 without high-risk features, and observation alone is appropriate for very low-risk patients 3
For very young patients, aspirin alone is recommended, with hydroxyurea reserved only for compelling indications due to long-term leukemogenic concerns, and consider interferon-alpha as an alternative if cytoreduction becomes necessary 1, 3, 4

The American Society of Clinical Oncology recommends targeting a platelet count <400 × 10⁹/L with hydroxyurea therapy, and monitoring complete blood counts every 4-8 weeks once stabilized 1, 2, 4

The National Comprehensive Cancer Network recommends switching to alternative therapy if platelet count remains >600 × 10⁹/L after 3 months of adequate dosing, or development of leg ulcers or unacceptable mucocutaneous toxicity, and second-line options include anagrelide and interferon-alpha or pegylated interferon 1, 2, 5

The National Comprehensive Cancer Network recommends using aspirin cautiously in patients with acquired von Willebrand disease or platelet counts >1,500 × 10⁹/L due to increased bleeding risk, and avoiding sequential cytotoxic agents as this significantly increases leukemic transformation risk 1, 3, 4, 6

The National Comprehensive Cancer Network recommends interferon-alpha as the only acceptable cytoreductive agent for pregnant patients requiring cytoreduction, as hydroxyurea is contraindicated, and low-dose aspirin plus low-molecular-weight heparin improves pregnancy outcomes, particularly in JAK2-mutated patients 4, 6